SPEC.ST
SpectraCure AB (publ) [SPEC.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SPEC.ST Stock Summary
Top 10 Correlated ETFs
SPEC.ST
Top 10 Correlated Stocks
SPEC.ST
In the News
SPEC.ST Financial details
Company Rating
-
Market Cap
227.29M
Income
-20.39M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
15
Optionable
No
Shortable
Yes
Earnings
12 Nov 2020
P/E
-16.14
Forward P/E
-
PEG
9.3
P/S
-
P/B
2.7
P/C
-
P/FCF
-10.32
Quick Ratio
6.53
Current Ratio
6.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.21
EPS next Y
-
EPS next Q
-
EPS this Y
-19.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.59%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
2.67%
-
-
-
-
SMA20
-13.98%
SMA50
-30.43%
SMA100
3.9%
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
-16%
ROC
-0.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.0-6.6
52W High
-83%
52W Low
-49%
RSI
22.71
Rel Volume
3.81
Avg Volume
105.88K
Volume
403.39K
Perf Week
-38.92%
Perf Month
-48.48%
Perf Quarter
-36.25%
Perf Half Y
-43.96%
-
-
-
-
Beta
0.71
-
-
Volatility
0.31%, 0.19%
Prev Close
-11.3%
Price
1.02
Change
-40%
Company Profile
- Volume Average 105.88K
- Market Capitalization 227.29M
- Employee 15
- CEO Dr. Masoud Khayyami Ph.D.
- Headquarters Lund,SE
- IPO Date 2015-07-01
-
Website
https://www.spectracure.com 
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.
